内科理论与实践2024，Vol.19Issue(2)：136-139,4.DOI:10.16138/j.1673-6087.2024.02.09
PCSK9抑制剂治疗非酒精性脂肪性肝病研究进展
Advances in study of PCSK9 inhibitors in treatment of non-alcoholic fatty liver disease
摘要
Abstract
Non-alcoholic fatty liver disease(NAFLD)is the chronic liver disease with the highest incidence rate,and its main cause is due to disorders of lipid metabolism and damage to the liver caused by ectopic fat deposition.Proprotein convertase bacillus subtilis/kexin type 9(PCSK9),as a lipid-regulating protease in vivo,plays a key role in abnormal lipid metabolism.Dyslipidemia levels can be significantly improved by inhibiting PCSK9 binding to receptors circulating in vivo.Therefore,PCSK9 inhibitors may improve the condition of NAFLD patients and achieve therapeutic effects.关键词
非酒精性脂肪性肝病/PCSK9抑制剂/胰岛素抵抗Key words
Nonalcoholic fatty liver disease/PCSK9 inhibitor/Insulin resistance分类
医药卫生引用本文复制引用
沈赟,徐一娇,韦晓,张瑞祥,刘超..PCSK9抑制剂治疗非酒精性脂肪性肝病研究进展[J].内科理论与实践,2024,19(2):136-139,4.基金项目
江苏省研究生科研创新计划项目(KYCX23＿2096) （KYCX23＿2096）
